Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
- 20 September 2021
- journal article
- letter
- Published by Elsevier BV in Annals of Oncology
- Vol. 33 (1), 107-108
- https://doi.org/10.1016/j.annonc.2021.09.009
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for CancerJAMA Oncology, 2021
- Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global dataCancer Letters, 2021
- Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patientsAnnals of Oncology, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020